NCT07643610Recruiting
BEAT-SHOCK Registry
BEAT-SHOCK (Basel Evaluation of Acute Therapy in Cardiogenic SHOCK) Registry
Source: ClinicalTrials.gov · Last updated 11 Jun 2026
Brief summary (registry, in English)
This regulation defines the purpose, the operational processes, and the organization of the registry BEAT-SHOCK (Basel Evaluation of Acute Therapy in cardiogenic SHOCK). It describes the requirements for collecting, storing, processing, managing and sharing health-related registry data.
- Status (registry)
- Recruiting
- Study type
- Observational
- Enrollment
- 8000 (estimated)
- First submitted
- 29 May 2026
- Start date
- 1 Oct 2025
- Primary completion date
- 1 Oct 2035
- Lead sponsor
- University Hospital, Basel, Switzerland
- Diseases
- Heart failure, Coronary artery disease
- NCT number
- NCT07643610
What you commit to
- Study type: Observational
- Planned participants: 8000
- From 1 Oct 2025 to the primary completion date, 1 Oct 2035
- 1 site in 1 country
- Visits and tests: ask the trial team, the registry does not list them
Built from the registry fields of ClinicalTrials.gov. It describes the study, not your situation.
Who cannot take part
Copied verbatim from ClinicalTrials.gov and grouped by topic. Only the trial team decides who can take part.
Age
- Age \<18 years
Other
- Refusal to provide informed consent by the patient or their legally authorized representative
Criteria the registry did not label
- Patients admitted with cardiogenic shock to the University hospital Basel (diagnosis at the time of admission) or development of cardiogenic shock during the hospital stay
- Age ≥18 years
- Provision of written ICF
- Clinical diagnosis of cardiogenic shock.
- impaired organ perfusion due to primary cardiac dysfunction,
- persistent systolic blood pressure (SBP) \<90 mmHg for ≥30 minutes, or the need for vasopressors, inotropes, or mechanical circulatory support (MCS) to maintain adequate perfusion and
- evidence of systemic hypoperfusion with arterial lactate ≥2 mmol/L or venous lactate ≥3 mmol/l and ≥1 of the following:
- Cold or clammy extremities
- Altered mental status
- Reduced urine output
- Signs of volume overload or congestion (on clinical exam, imaging, or invasive monitoring)
- Patients with normotensive cardiogenic shock (SBP ≥90 mmHg without vasopressors or MCS) may also be included if clear signs of hypoperfusion (arterial lactate ≥2 mmol/L or venous lactate ≥3 mmol/l) and cardiac dysfunction are present and alternative causes are excluded
Age in the registry: 18 years to - · Sex: All · Does not accept healthy volunteers
Sites (1)
Sites in registry order. Pick your city on the disease page to sort them by distance.
| Site | City | Country | Site status |
|---|---|---|---|
| University Hospital Basel Coordinator of this site? Confirm its status | Basel | Switzerland | Recruiting |
This page is information, not medical advice. Discuss any trial with your doctor.